Skip to main content
. 2022 Jul 5;12:936145. doi: 10.3389/fonc.2022.936145

Figure 2.

Figure 2

Effect of GHRA on response of syngeneic mouse melanoma tumors to cisplatin treatment in vivo. (A) Mouse Fluc-B16-F10 cells grafted intradermally on the right flank of syngeneic C57BL6/J wild-type (WT) and GHA mice (transgenic for bGH G119K GHR antagonist) (n=8). The changes in tumor volume (Fluc-B16-F10 in WT and GHA mice) from digital caliper measurement and representative tumors post-dissection (A) and tumor mass (B) corroborate suppressed tumor growth in GHA mice and improved tumoral response to cisplatin in the GHA mice. The qPCR analysis of ABC transporter RNA expression involved in multi-drug efflux from the tumors in WT and GHA mice (C) and western-blot assessment of GH downstream signaling and ABC transporter protein levels (D) are shown. (E) The changes in ABC transporter RNA level in B16-F10 cells in culture when treated with serum collected from WT and GHA mice (*p < 0.05, mouse studies – repeated measure using SPSS; other assays - Students t test, n = 3).